Plus Therapeutics Inc (PSTV NASDAQ) stock market data APIs
$0.2973
0.01(3.4%)
as of July 3, 2025
Try our APIs with
free plan!
Plus Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Prev. Close
0.2973
Open
0.3086
High
0.3086
Low
0.2899
52 wk Range
0.16-2.31
Market Cap
15 116 K
Shares Outstanding
50 999 K
Revenue
5 206 K
EPS
-0.5669
Beta
0.624
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Plus Therapeutics Inc data using free add-ons & libraries
Get Plus Therapeutics Inc Fundamental Data
Plus Therapeutics Inc Fundamental data includes:
- Net Revenue: 5 206 K
- EBITDA: -14 218 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -0.2933
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Plus Therapeutics Inc News
New
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award from...
VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14%
(RTTNews) - What's driving the momentum in the following stocks? Vor Bio, Inc. (VOR) has secured ex-Greater China rights from RemeGen Co., Ltd. to develop and commercialize Telitacicept, a novel dual...
Plus Therapeutics to launch CNS cancer diagnostic platform in 2025
HOUSTON - Plus Therapeutics, Inc. (NASDAQ:PSTV) plans to begin commercial rollout of its CNSide cerebrospinal fluid diagnostic platform in the second half of 2025, according to a company statement rel...
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
